Life Sciences

  • June 04, 2026

    Inotiv Gets Cash Access To Pursue Ch. 11 Prepack Track

    Bankrupt drug research and development company Inotiv Inc. received interim approval on Thursday to access a $25 million bankruptcy loan as it pursues a prepackaged balance sheet restructuring in Texas court.

  • June 04, 2026

    Catalent Investors Say No Objections To $78M Deal, Fee Bid

    Investors seeking final approval of a $78 million securities fraud settlement with Catalent told a New Jersey federal court that the proposed deal and fee bid are free of objections, arguing the positive response further supports the court's approval of the settlement.

  • June 04, 2026

    US Middle Market PE Surge Expected After Strong 2025

    U.S. middle market private equity dealmakers are signaling renewed optimism, with the vast majority expecting a meaningful jump in buyout activity over the next two years after a robust 2025, according to survey results published on Thursday. 

  • June 04, 2026

    Supreme Court Shuts Down 'Skinny Label' Drug Patent Suit

    The U.S. Supreme Court on Thursday ended a patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, saying Amarin Pharma Inc. had not plausibly alleged that Hikma encouraged healthcare providers to infringe its patents.

  • June 03, 2026

    AbbVie Loses Miss. Discount Drug Law Challenge For Good

    A Mississippi federal judge on Wednesday threw out a suit brought by AbbVie and other pharmaceutical manufacturers that participate in Medicaid challenging a law barring their interference with the distribution of discounted prescriptions to pharmacies serving low-income patients.

  • June 03, 2026

    Medtronic Unit Must Face Bellwether Hernia Mesh Claims

    A Massachusetts federal judge has largely cleared the way for bellwether claims in multidistrict litigation over Covidien's hernia mesh, finding that a reasonable jury could find the Medtronic subsidiary failed to adequately warn physicians about certain risks.

  • June 03, 2026

    Balwani Takes Theranos Conviction Challenge To Justices

    Former Theranos executive Ramesh "Sunny" Balwani is asking the U.S. Supreme Court to review his criminal fraud conviction and nearly 13-year prison sentence, arguing that the Ninth Circuit used the wrong review doctrine in rejecting his argument that prosecutors had failed to correct allegedly false testimony given by investor victims.

  • June 03, 2026

    'This Is Their Document': Jury Told J&J Docs Prove Talc Lies

    Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.

  • June 03, 2026

    Squires Institutes 3 Patent Reviews, Denies 3 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted three requests for review of patents under the America Invents Act, while turning down three other petitions.

  • June 03, 2026

    Ill. Court Blocks Fla. Suit Targeting Gender Care Policies

    An Illinois federal judge blocked the Florida attorney general's lawsuit targeting medical groups' policies on youth gender-affirming care, saying there's sufficient jurisdiction over Sunshine State officials because of a potential nationwide chilling effect the enforcement action caused.

  • June 03, 2026

    Trans Youth Sue NYU Langone, DOJ To Bar Records Release

    A group of transgender minors and young adults who received gender dysphoria care at NYU Langone urged a New York federal court to bar the U.S. Department of Justice from accessing their sensitive health records through a criminal subpoena.

  • June 03, 2026

    Purdue Pharma Heir Sues Son Over Sackler Matriarch's Estate

    Former Purdue Pharma LP President Richard Sackler has appealed a Connecticut probate court decision favoring his son David Sackler in a dispute over his mother Beverly Sackler's estate, saying a judge ignored self-dealing rules when approving his son's request to assign trust interests to a public charity.

  • June 03, 2026

    BigLaw Insider Trading Defendants Have Big-Name Legal Help

    An insider trading case involving nonpublic information prosecutors say was stolen from some of the largest law firms in the U.S. has ensnared more than two dozen defendants, many of whom have turned to lawyers with notable clients including Donald Trump, Harvey Weinstein and Luigi Mangione.

  • June 03, 2026

    1st Circ. Panel Seems Poised To Uphold RI Drug Pricing Law

    The majority of a First Circuit panel seemed unlikely Wednesday to upend a Rhode Island law that blocks drug manufacturers from imposing restrictions on healthcare providers and contract pharmacies in a federal prescription drug discount program, appearing unconvinced of an argument that states can't interfere with federal government programs. 

  • June 03, 2026

    Supplier Can't Force Arbitration Of Worker's Wage Suit

    A proposed wage class action against a medical and industrial gas supplier can proceed in court, a Washington federal judge ruled, finding that a former worker's arbitration agreement with a staffing agency did not apply.

  • June 03, 2026

    IVF Patients Say Natera Profited Off Ineffective Embryo Tests

    A proposed class of in vitro fertilization patients are suing Natera Inc. in California federal court, alleging that it falsely advertised the efficacy and importance of its preimplantation genetic testing to rake in hundreds of millions of dollars from patients looking to conceive.

  • June 03, 2026

    Drug Research Co. Inotiv Files Ch. 11 To Cut $325M In Debt

    Contract drug research and development company Inotiv Inc. filed a prepackaged Chapter 11 case Wednesday in Texas bankruptcy court with $489 million of debt and support from the majority of its creditors for its reorganization plan.

  • June 03, 2026

    Paul Weiss Hires Deals Pro From Dechert In NY

    Paul Weiss Rifkind Wharton & Garrison LLP announced Monday that it has welcomed a corporate partner from Dechert LLP, touting his role in large mergers and acquisitions in the life sciences, financial services, consumer and retail, energy, technology and industrial sectors.

  • June 02, 2026

    Talc Tester Says J&J Never Pressured Him To Hide Asbestos

    A geologist on Tuesday told a California jury considering bellwether claims that Johnson & Johnson's talc products caused their deadly ovarian cancer that he tested the products for years and the company never asked him to lie about any results, even after he discovered asbestos in a World War II-era bottle.

  • June 02, 2026

    Generics Makers Tell 3rd Circ. Buyers Too Few For Class

    Two pharmaceutical companies embroiled in decadelong litigation over the alleged price-fixing of generic drugs told a Third Circuit panel on Tuesday that groups of drug buyers either didn't have the numbers necessary to support class certification or were not clearly identifiable.

  • June 02, 2026

    FTC Sues Supplement Co. Over Mental Health, Income Claims

    The Federal Trade Commission on Tuesday sued dietary supplement brand Amare Global Holdings Inc. in California federal court, alleging it misleads buyers by falsely claiming its products can treat mental health issues, while also misleading prospective "brand partners" about how much they are likely to make under Amare's program.

  • June 02, 2026

    DLA Piper Brings On A&O Shearman M&A Partner In SF

    DLA Piper has announced it is pushing forward with its "strategic expansion" in Northern California with the addition of "a market-leading dealmaker" from Allen Overy Shearman Sterling.

  • June 02, 2026

    Pharma Co. Inks $7M Deal To End Investor's Cancer Study Suit

    A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.

  • June 02, 2026

    Judge Ends Nausea Drug Suit After Invalidating Other Patents

    A federal judge has ruled one set of patents covering the nausea drug Cinvanti was invalid and found a set asserted in another suit not infringed.

  • June 02, 2026

    Lack Of Indemnity Liability Doomed Vax IP Case, Judge Says

    Drug developer Acuitas Therapeutics Inc. failed to show that it would have to indemnify BioNTech as a result of GlaxoSmithKline's patent infringement lawsuit against BioNTech and Pfizer over the COVID-19 vaccine, a Delaware federal judge has said.

Expert Analysis

  • FDA's Biosimilarity Guidance Holds Uncertain Implications

    Author Photo

    The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.